{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-105457","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-10-01T12:00:17+00:00","discovered_at":"2026-10-01T12:05:00.253764+00:00","generated_at":"2026-10-12T14:15:58.820149+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Allarity cites patent awards, CLIA lab certification to advance stenoparib DRP companion diagnostic","bullets":["Allarity says recent patent awards plus CLIA certification of its in-house lab let it retain sole control of the stenoparib-DRP test as a companion diagnostic.","Stenoparib-DRP comprises a 414-gene expression signature including genes tied to WNT pathway activity; DRP tests have been developed for dozens of cancer therapies.","At AACR 2026, an exploratory analysis of a prior Phase 2 cohort of advanced ovarian cancer patients on twice-daily stenoparib linked higher pretreatment DRP scores to longer overall survival.","CEO Thomas Jensen said the DRP-survival association helps inform the path toward FDA approval; stenoparib remains the principal development focus.","No financial results, patient counts, partnership terms or pivotal-trial timeline were disclosed in the update."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-105457","json":"https://secwatch.observer/filing/0001213900-26-105457.json","markdown":"https://secwatch.observer/filing/0001213900-26-105457.md","text":"https://secwatch.observer/filing/0001213900-26-105457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026105457/0001213900-26-105457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026105457/ea0307298-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:15:58.820149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}